Hatay Pharmaceutical Joint Stock Pharmaceutical Import Profile — Vietnam (DGFT 2022–2026)

Name: Hatay Pharmaceutical Joint Stock Pharmaceutical Import Records from India — 2 Products, $750.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hatay Pharmaceutical Joint Stock — Pharmaceutical Importer Profile (2026) | 2 Products, $750.0K Trade | TransData Nexus

Hatay Pharmaceutical Joint Stock

Pharmaceutical Importer · Vietnam · Gastrointestinal Focus · $750.0K Total Trade · DGFT Verified

Hatay Pharmaceutical Joint Stock is a pharmaceutical importer based in Vietnam with a total trade value of $750.0K across 2 products in 2 therapeutic categories. Based on 15 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hatay Pharmaceutical Joint Stock sources from 22 verified Indian suppliers, with Wockhardt Limited accounting for 42.8% of imports.

Hatay Pharmaceutical Joint Stock — Import Portfolio & Supplier Network

Hatay Pharmaceutical Joint Stock import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hatay Pharmaceutical Joint Stock?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Wockhardt Limited	$3.8M	115	42.8%
Micro Labs Limited	$1.4M	33	16.1%
Flamingo Pharmaceuticals Limited

What Formulations Does Hatay Pharmaceutical Joint Stock Import?

Formulation	Value	Ships
Wosulin 30/70 40iu/ML, 10ML vial	$300.0K	9
Loperamide hcl capsules USP 2 MG	$254.0K	6
Wosulin 30/70 cartridge 100iu 3ML 1s	$236.1K	5
Cefalexin capsules BP 500MG	$200.0K	4
Inore-kit (combikit of lansoprazole +	$200.0K	4
Myroken-200 (cefixime capsules 200MG)	$200.0K	4
Meritaxi 1GM INJ with wfi 10ML -mfg.	$200.0K	4
Glaritus dispopen-2	$180.2K	5
Wosulin 30/70 vial 40iu 10ML -green	$150.0K	3
Cimetidine tablets USP 200MG	$150.0K	3
Wosulin 30/70 vial 40iu 10ML (+19830 vials -free goods of no commercial value	$150.0K	3
Zy 10 forte capsules (Each soft gelatincapsule contains : ubidecarenone (coenzym q10) 100 MG)(98000 packs)(03x10c	$150.0K	3
Glaritus dispopen 100iu 3ML 1s -green	$126.4K	3
Glaritus dispopen - 2 (insulin glargineinjection 100iu/ML, 3ML)	$119.7K	4
Pharmaceutical goods/harmless medicinesfor human use - pdsolone-125 MG (detailas per invoice) (100000 boxes	$110.0K	3

Hatay Pharmaceutical Joint Stock imports 221 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Loperamide	Gastrointestinal	$400.0K	8	0.5%	10
2	Tinidazole	Advanced Antibiotics	$350.0K	7	1.9%	4

Hatay Pharmaceutical Joint Stock imports 2 pharmaceutical products across 2 categories into Vietnam totaling $750.0K.

Hatay Pharmaceutical Joint Stock — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hatay Pharmaceutical Joint Stock Company, commonly known as Hataphar, is a prominent Vietnamese pharmaceutical enterprise established in 1965. The company specializes in the manufacturing, marketing, wholesale and retail trading, import, and export of pharmaceutical products, medicinal materials, vaccines, and medical equipment. Additionally, Hataphar produces and trades in cosmetics, functional foods, and chemicals for laboratory tests. Over the decades, Hataphar has solidified its position as a leading player in Vietnam's pharmaceutical sector, recognized for its commitment to quality and innovation. (hataphar.com.vn)

Headquartered at 10 A Quang Trung Street, Ha Dong Ward, Hanoi, Vietnam, Hataphar operates multiple facilities, including a factory that meets PIC/S and Japan-GMP standards, reflecting its dedication to adhering to international pharmaceutical manufacturing standards. (hataphar.com.vn) The company is publicly listed on the Hanoi Stock Exchange under the ticker symbol DHT, indicating its status as a publicly traded entity.

2Distribution Network

Hataphar boasts a comprehensive distribution network that spans all 63 provinces of Vietnam, ensuring widespread availability of its products nationwide. This extensive reach is supported by a robust logistics infrastructure, including warehouses strategically located to facilitate efficient storage and distribution. The company's adherence to Good Distribution Practice (GDP) and Good Pharmaceutical Practice (GPP) standards underscores its commitment to maintaining the integrity and quality of its products throughout the supply chain. (hataphar.com.vn)

3Industry Role

In Vietnam's pharmaceutical supply chain, Hataphar functions as a primary wholesaler and distributor. The company imports pharmaceutical products, including raw materials and finished formulations, and supplies them to domestic pharmaceutical manufacturers and healthcare providers. By sourcing raw materials from developed countries such as France, Germany, Switzerland, Japan, South Korea, and China, Hataphar ensures a steady supply of high-quality inputs for the Vietnamese pharmaceutical industry.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hatay Pharmaceutical Joint Stock

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hataphar's sourcing strategy reveals a significant concentration in its supplier base. The company imports a total of 221 unique formulations from 22 Indian suppliers, with the top five suppliers accounting for 100% of the total import value. This indicates a high dependency on a select group of suppliers, which could pose risks related to supply chain disruptions or changes in supplier terms. However, the consistent volume of shipments and the long-standing nature of these relationships suggest a stable and strategic partnership, likely aimed at ensuring product quality and favorable pricing.

2Supply Chain Resilience

The resilience of Hataphar's Indian supply chain is bolstered by its diversified sourcing from multiple suppliers, reducing the impact of potential disruptions from any single source. The company's import of 221 unique formulations indicates a broad product portfolio, which can mitigate risks associated with over-reliance on specific products. Additionally, Hataphar's adherence to international manufacturing standards, such as PIC/S and Japan-GMP, ensures that its suppliers maintain high-quality production practices, further enhancing the reliability of the supply chain. (hataphar.com.vn)

3Strategic Implications

Importing Pharmaceuticals into Vietnam — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Vietnam

1Regulatory Authority & Framework

In Vietnam, the primary regulatory body overseeing pharmaceutical imports is the Drug Administration of Vietnam (DAV), operating under the Ministry of Health. The importation of pharmaceutical products is governed by the Law on Pharmacy No. 105/2016/QH13, which outlines the requirements for drug registration, import licensing, and market authorization. Decree No. 54/2017/ND-CP provides detailed provisions for implementing the Law on Pharmacy, including conditions for obtaining import licenses and the registration process for imported drugs. (hmlf.vn)

2Import Licensing & GMP

To import pharmaceutical products into Vietnam, companies must obtain an import license issued by the Ministry of Health. This license is contingent upon the drug being registered with the DAV and granted Market Authorization (MA). The registration process involves submitting a comprehensive dossier that includes detailed information about the drug's safety, efficacy, and quality. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) standards recognized by the DAV, ensuring that manufacturing processes meet international quality benchmarks. (hmlf.vn)

3Quality & Labeling

Hatay Pharmaceutical Joint Stock — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hataphar's focus on importing products in the gastrointestinal and advanced antibiotics therapeutic categories aligns with the significant demand for these medications in Vietnam. The company's top two imported products, Loperamide and Tinidazole, cater to prevalent health concerns, indicating a strategic approach to meet the therapeutic needs of the Vietnamese population. This targeted product strategy underscores Hataphar's commitment to addressing critical health issues through its import portfolio.

2Sourcing Profile

Hataphar's sourcing strategy emphasizes the importation of generic drug formulations, primarily from India, to offer cost-effective solutions to the Vietnamese market. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market products that can be swiftly distributed. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a strategic partner for Hataphar's procurement needs.

3Market Positioning

By importing a diverse range of pharmaceutical products, Hataphar serves multiple segments of the Vietnamese market, including retail pharmacies, hospitals, and government tenders. The company's extensive distribution network and adherence to international quality standards position it as a reliable supplier across various healthcare settings, catering to both urban and rural populations.

Seller's Guide — How to Become a Supplier to Hatay Pharmaceutical Joint Stock

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Hataphar's supply chain by meeting the company's stringent quality standards and offering competitive pricing. Potential gaps in Hataphar's current sourcing include the need for additional suppliers to diversify its supplier base and enhance supply chain resilience. Indian exporters can capitalize on this by ensuring compliance with Vietnamese regulatory requirements and establishing strong partnerships with Hataphar.

2Requirements & Qualifications

Indian exporters aiming to supply Hataphar must obtain an import license from the Ministry of Health in Vietnam, which requires the drug to be registered with the Drug Administration of Vietnam and granted Market Authorization. Compliance with Good Manufacturing Practice (GMP) standards recognized by the DAV is mandatory. Additionally, products must meet Vietnamese labeling requirements, including the use of the Vietnamese language and adherence to serialization mandates. (hmlf.vn)

3How to Approach

Frequently Asked Questions — Hatay Pharmaceutical Joint Stock

What products does Hatay Pharmaceutical Joint Stock import from India?

Hatay Pharmaceutical Joint Stock imports 2 pharmaceutical products across 2 categories. Top imports: Loperamide ($400.0K), Tinidazole ($350.0K).

Who supplies pharmaceuticals to Hatay Pharmaceutical Joint Stock from India?

Hatay Pharmaceutical Joint Stock sources from 22 verified Indian suppliers. The primary supplier is Wockhardt Limited (42.8% of imports, $3.8M).

What is Hatay Pharmaceutical Joint Stock's total pharmaceutical import value?

Hatay Pharmaceutical Joint Stock's total pharmaceutical import value from India is $750.0K, based on 15 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hatay Pharmaceutical Joint Stock focus on?

Hatay Pharmaceutical Joint Stock imports across 2 categories. The largest: Gastrointestinal (53.3%), Advanced Antibiotics (46.7%).

Get Full Hatay Pharmaceutical Joint Stock Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.